Human anti-CD38 monoclonal antibody for multiple myeloma that mediates ADCC, CDC, ADCP, and apoptosis of CD38+ plasma cells and depletes CD38+ immunosuppressive cells (Tregs, Bregs, MDSCs), enhancing T/NK-cell responses.
Human anti-CD38 IgG1κ monoclonal antibody that binds CD38 on malignant plasma cells, inducing ADCC, CDC, ADCP, and direct apoptosis; also depletes CD38+ immunosuppressive cells (Tregs, Bregs, MDSCs), thereby enhancing T- and NK-cell antitumor responses.
YES
DIRECT
Daratumumab binds CD38 on target cells and triggers Fc-mediated ADCC by NK cells, complement-dependent cytotoxicity, antibody-dependent phagocytosis, and can induce direct apoptosis upon crosslinking.
Approved HER2-directed antibody–drug conjugate that, after binding and internalization via HER2, releases the microtubule inhibitor DM1; preserves trastuzumab’s HER2 blockade and Fc-mediated ADCC.
HER2-targeted monoclonal antibody (trastuzumab) linked to the maytansinoid DM1. After binding HER2 on tumor cells and internalization, lysosomal processing releases DM1, a microtubule inhibitor that induces mitotic arrest and apoptosis; concurrently retains trastuzumab’s HER2 signaling blockade and Fc-mediated ADCC.
NO
INDIRECT
T-DM1 targets HER2, is internalized, and releases DM1 that binds beta-tubulin to inhibit microtubules; beta-tubulin expression alone does not lead to killing without HER2-mediated delivery.
Humanized anti-GD2 IgG1 monoclonal antibody that binds GD2 on tumor cells and mediates antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity.
Humanized anti-GD2 IgG1 monoclonal antibody that binds GD2 on tumor cells and induces immune-mediated killing via Fcγ receptor–driven antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to lysis of GD2-expressing cancer cells.
YES
DIRECT
The anti-GD2 IgG1 binds GD2 on target cells and recruits immune effectors via its Fc to trigger ADCC (e.g., NK cell–mediated killing) and activates complement for CDC, leading to lysis of GD2-expressing cells.
Anti-CD20 monoclonal antibody that mediates ADCC, complement activation, and apoptosis of CD20-positive B cells.
Anti-CD20 monoclonal antibody that binds CD20 on B cells and induces their depletion via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis.
YES
DIRECT
Rituximab binds CD20 on B cells and triggers killing via Fc-mediated ADCC (NK cells/macrophages), complement-dependent cytotoxicity (C1q activation), and direct apoptosis upon CD20 crosslinking.
Anti-HER2 antibody–drug conjugate (RC48) that binds HER2, is internalized, and releases the microtubule-disrupting payload MMAE; can also induce ADCC.
Anti-HER2 IgG1 antibody–drug conjugate that binds HER2, is internalized, and releases the cytotoxic payload monomethyl auristatin E (MMAE) to inhibit tubulin polymerization, leading to microtubule disruption, G2/M arrest, and apoptosis; the IgG1 Fc can also induce ADCC.
YES
DIRECT
The HER2-binding ADC is internalized and releases MMAE, which inhibits tubulin polymerization leading to microtubule disruption, G2/M arrest, and apoptosis; IgG1 Fc can also mediate ADCC against HER2+ cells.